Punt CJ - Search Results

1

BRAF mutation in metastatic colorectal cancer.

Tol J, Nagtegaal ID, Punt CJ. Tol J, et al. Among authors: punt cj. N Engl J Med. 2009 Jul 2;361(1):98-9. doi: 10.1056/NEJMc0904160. N Engl J Med. 2009. PMID: 19571295 No abstract available.

2

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Cunningham D, et al. Among authors: punt cj. Lancet. 1998 Oct 31;352(9138):1413-8. doi: 10.1016/S0140-6736(98)02309-5. Lancet. 1998. PMID: 9807987 Clinical Trial.

3

Treatment of liver metastases from colorectal cancer.

Tol J, Punt CJ. Tol J, et al. Among authors: punt cj. Neth J Med. 2006 May;64(5):133-5. Neth J Med. 2006. PMID: 16702610

4

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ. Koopman M, et al. Among authors: punt cj. Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1. Lancet. 2007. PMID: 17630036 Clinical Trial.

5

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ; Dutch Colorectal Cancer Group study. Kweekel DM, et al. Among authors: punt cj. Br J Cancer. 2008 Jul 22;99(2):275-82. doi: 10.1038/sj.bjc.6604461. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594531 Free PMC article. Clinical Trial.

6

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Tol J, et al. Among authors: punt cj. N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. N Engl J Med. 2009. PMID: 19196673 Clinical Trial.

7

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Cohen SJ, et al. Among authors: punt cj. Ann Oncol. 2009 Jul;20(7):1223-9. doi: 10.1093/annonc/mdn786. Epub 2009 Mar 12. Ann Oncol. 2009. PMID: 19282466

8

More is less -- combining targeted therapies in metastatic colorectal cancer.

Punt CJ, Tol J. Punt CJ, et al. Nat Rev Clin Oncol. 2009 Dec;6(12):731-3. doi: 10.1038/nrclinonc.2009.168. Nat Rev Clin Oncol. 2009. PMID: 19942926 Review.

9

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ. Tol J, et al. Among authors: punt cj. Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Clin Ther. 2010. PMID: 20399983 Review.

10

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Tol J, et al. Among authors: punt cj. Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21. Eur J Cancer. 2010. PMID: 20413299 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results